TABLE 2.
Demographics and clinical baseline characteristics of the pooled patient population included in the meta‐analysis
| Baseline demographics | n | Mean | SD | Median | Min. | Max. |
|---|---|---|---|---|---|---|
| Age (y) | 10 236 | 66.2 | 7.20 | 66 | 47 | 94 |
| Body weight (kg) | 10 206 | 83.2 | 13.60 | 82 | 37 | 179 |
| Height (cm) | 10 204 | 174.1 | 7.48 | 175 | 132 | 208 |
| Baseline PSA (ng/mL) | 10 206 | 3.98 | 2.10 | 3.4 | 0.6 | 23.2 |
| Baseline prostate volume (mL) | 9875 | 54.53 | 23.00 | 48.5 | 16.59 | 296.89 |
| Baseline IPSS | 10 228 | 16.48 | 6.10 | 16 | 1 | 35 |
| Baseline maximum urinary flow (mL/s] | 9163 | 10.49 | 3.59 | 10.20 | 2.2 | 36.2 |
| BMI (kg/m2) | 10 210 | 27.44 | 3.99 | 26.91 | 12.36 | 59.73 |
| Duration of BPH symptoms (y) | 9881 | 5.17 | 4.77 | 4.00 | 0 | 54.8 |
| Time from BPH diagnosis (y) | 10 080 | 2.65 | 4.26 | 2.3 | 0.58 | 52 |
| Alcohol use (yes/no) | 6198/3992 | |||||
| Sexually active (yes/no) | 7244/2984 | |||||
| Race (White/Black/Hispanic/Asian) | 9268/229/276/374 | |||||
| Smoking status (yes/no) | 1239/8998 | |||||
| Treatment information | Placebo | WW | Tamsulosin | Dutasteride | Combination therapy | |
| Number of subjects | 2158 | 373 | 1611 | 3790 | 2143 | |
| Treatment duration: | ||||||
| ≤12 mo | 475 | 44 | 180 | 659 | 610 | |
| ≤18 mo | 638 | 60 | 296 | 872 | 694 | |
| ≤24 mo | 2158 | 373 | 381 | 1181 | 940 | |
| <36 mo | 2158 | 373 | 536 | 1625 | 1125 | |
| <48 mo | 2158 | 373 | 1611 | 3790 | 2143 | |
Abbreviations: BMI, body mass index; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score (questionnaire); PSA, prostate‐specific antigen; WW, watchful waiting.